VBWG
Data alert

HOPE: New validation for the importance of tissue ACE inhibition

The results of the recently published HOPE (Heart Outcomes Prevention Evaluation) study provide powerful confirmation of the clinical benefits of tissue angiotensin-converting enzyme (ACE) inhibition, now strikingly demonstrated in patients at high risk for cardiovascular events.1 This important trial is the latest in a series of carefully conducted studies supporting the hypothesis that tissue ACE inhibition is a key factor in decreasing morbidity and mortality due to coronary disease.

References are listed at the end of the Data Alert.





DA2.ppt

Download DA2.ppt (8 slides - 0.7MB)

Slide 1 Slide 2 Slide 3 Slide 4 Slide 5 Slide 6 Slide 7 Slide 8
Data_Alert.pdf (0.3MB)Data_Alert.pdf (0.3MB)


ACEangiotensincardiovascularconfirmationdemonstratedenzymeEvaluationinhibitionPreventionpublishedstrikinglytissuevalidation

Related at vwbg.org

Data and Commentary:The HOPE Study

Effects of angiotensin-converting enzyme inhibition on cardiovascular events in high-risk patients

The Heart Outcomes Prevention Evaluation Study Investigators.

The CHARM program: Enhancement of RAAS manipulation in heart failure

Clinical trials have demonstrated the benefits of angiotensin-converting enzyme (ACE) inhibitors 1 and ß-blockers 2-4 in patients with chronic heart failure (HF) and reduced left ventricular ejection fraction (LVEF).

Angiotensin-(1-7): New insights into the benefits of tissue ACE inhibition

Emerging new data are expanding our understanding of the renin-angiotensin system (RAS).
More related